Johnson & Johnson (J&J) has reported sales of $25.53bn in the second quarter (Q2) of 2023, indicating an increase of 6.3% as against $24.02bn in the same quarter of 2022.

Net earnings stood at $5.14bn for the quarter, a rise of 6.9% from $4.81bn year-on-year.

Diluted earnings per share (EPS) rose by 8.9% to $1.96 compared to $1.80 in Q2 2022.

Reported year-on-year sales in the US region increased by 10.2% to $13.44bn in Q2 2023, against $12.19bn in Q2 2022.

During Q2 2023, international sales increased by 2.2% while worldwide sales rose by 6.3%.

In the pharmaceutical segment of the company, a 3.1% rise in sales to $13.73bn in Q2 2023 was reported, compared to $13.31bn in the same quarter of 2022.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

A 6.2% rise in worldwide adjusted operational sales, excluding those of the company’s Covid-19 vaccine, was reported in the second quarter of 2023.

The growth was driven by Darzalex, Erleada, Carvykti, Stelara, Tremfya, Uptravi, Opsumit and Spravato.

The company also reported a 12.9% surge in sales to $7.78bn in Q2 2023 as against $6.89bn in 2022 in the medtech segment.

J&J board chairman and CEO Joaquin Duato stated: “Our robust performance in the second quarter and the first half of 2023 is a testament to the hard work and commitment of our colleagues around the world. 

“We are entering the back half of the year from a position of strength with numerous catalysts, including becoming a two-sector company focused on pharmaceutical and medtech innovation.”

The company has raised its guidance midpoints for the full-year 2023 for adjusted operational sales from 5% to 6.5% while the adjusted operational EPS (diluted) was also raised to 6% from 5%.

In April 2023, the company reported a 5.6% rise in sales to $24.75bn in Q1 2023.